Kim Hee Seung, Kim Miseon, Luo Yanlin, Lee Maria, Song Yong Sang
Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea.
Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
J Surg Oncol. 2017 Sep;116(4):492-499. doi: 10.1002/jso.24696. Epub 2017 Jul 10.
To investigate favorable factors of nerve-sparing radical hysterectomy (NSRH) for preserving the pelvic autonomic nerves and subsequent bladder function and to compare the safety between NSRH and conventional radical hysterectomy (CRH) for cervical cancer.
We recruited 87 consecutive patients with IB1-IIA cervical cancer who underwent NSRH, and reviewed the information of 81 patients who received CRH for historical comparisons. One gynaecologic oncologist performed all operations.
IB1 disease was the only favorable factor for unilateral or bilateral preservation (adjusted OR, 0.245; 95% CI, 0.077-0.774), whereas IB1 disease and squamous cell carcinoma (SqCC) were favorable for bilateral preservation (adjusted ORs, 0.336 and 0.116; 95% CIs, 0.162-0.982 and 0.023-0.581). The median duration of postoperative catheterization (DPC) was different among bilateral, unilateral and failed preservation (median 6 vs 18 vs 90 days; P < 0.001). The median DPC was shorter in NSRH patients with stage IB1 disease or SqCC (7 vs 14 days; P < 0.05) despite no difference between NSRH and CRH in those with IB2-IIA disease or non-SqCC. Survival was not different between NSRH and CRH patients.
IB1 disease and SqCC are favorable for preserving the pelvic autonomic nerves and subsequent bladder function without compromising survival outcomes in patients treated with NSRH.
探讨保留盆腔自主神经的根治性子宫切除术(NSRH)保留盆腔自主神经及后续膀胱功能的有利因素,并比较NSRH与传统根治性子宫切除术(CRH)治疗宫颈癌的安全性。
我们连续招募了87例行NSRH的IB1-IIA期宫颈癌患者,并回顾了81例接受CRH患者的信息以进行历史对照。所有手术均由一名妇科肿瘤学家完成。
IB1期疾病是单侧或双侧保留神经的唯一有利因素(校正OR,0.245;95%CI,0.077-0.774),而IB1期疾病和鳞状细胞癌(SqCC)有利于双侧保留神经(校正OR分别为0.336和0.116;95%CI分别为0.162-0.982和0.023-0.581)。双侧、单侧和保留神经失败患者的术后导尿中位持续时间(DPC)不同(中位时间分别为6天、18天和90天;P<0.001)。IB1期疾病或SqCC的NSRH患者的中位DPC较短(7天对14天;P<0.05),尽管IB2-IIA期疾病或非SqCC患者的NSRH与CRH之间无差异。NSRH和CRH患者的生存率无差异。
IB1期疾病和SqCC有利于保留盆腔自主神经及后续膀胱功能,且不影响接受NSRH治疗患者的生存结局。